Sparkle Clean Tech and Aquadei Launch Global Alliance to Transform Oil & Gas Water Treatment with Next-Gen Nanobubble Technology
4.11.2025 17:02:00 CET | Business Wire | Press Release
Sparkle Clean Tech (SCT)(exclusive global licensee of Siemens Energy’s oil & gas water-treatment IP) and Aquadei, LLC have formed a strategic alliance to deploy Aquadei’s proprietary nanobubble and hydrodynamic cavitation technologies to oil & gas operations globally. This partnership is set to drive advanced water treatment methods, delivering measurable operational, economic and environmental benefits across the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104652683/en/
Nanobubble Technology in Oil & Gas: Performance Advantages
Nanobubbles (gas particles smaller than 200 nanometers) feature extraordinary physical surface and interfacial properties that enhance how oil and solids interact in water. When paired with SCT’s separation technologies, these ultrafine bubbles enable more efficient separation, lower chemical consumption, and greater process stability.
Unlike traditional flotation systems that rely on buoyancy alone, SCT and Aquadei’s approach leverages hybrid nanobubble + microbubble flotation — a design proven to improve attachment between bubbles and oil droplets. Priming the process through a hydrodynamic cavitation pre-treatment installed inline before a flotation unit, this compact device uses controlled pressure differentials to generate localized microjets and shockwaves that disrupt stubborn emulsions and naturally generate stable nanobubbles. This process physically “conditions” produced water — enlarging fine oil droplets and enhancing their readiness for flotation capture. The nanobubbles modify droplet surfaces, promote coalescence, and act as bridges to the larger microbubbles that provide lift. The result: a faster, cleaner, and more energy-efficient separation process.
Operational and Environmental Impact
Joint deployments are expected to deliver step-change performance in oilfield water management:
- Up to 40% improved oil recovery rates (Enhanced Oil Recovery, EOR)
- 30% reduction in chemical treatment costs (Produced Water Treatment)
- Enhanced pipeline lifespan through biofilm and scale suppression
- Ultra-efficient delivery of gases (O2, O3, CO2), minimizing waste and energy
- Cleaner water, lower chemical dependency, and higher operational efficiency for sustainable, low-impact oilfield workflows
Strategic Partnership Overview
By combining SCT’s global reach and Siemens-licensed portfolio with Aquadei’s innovative nanobubble and ultrafine technologies, the alliance aims to deliver step-change reductions in operational costs, chemical use, and environmental impact. Joint projects will begin deployment in North America and the Middle East in early 2026.
About Aquadei, LLC
Aquadei is a water-innovation company specializing in nanobubble and ultrafine bubble technologies for wellness, industrial water efficiency, and environmental regeneration. Through its GAIA Water acquisition, Aquadei advances sustainable solutions that combine quantum particle science with real-world applications.
Website: https://aquadei.net/, https://gaiawater.com/
About SCT Technologies
Sparkle Clean Tech (SCT) delivers next-generation oil & gas water-treatment systems based on Siemens Energy’s licensed IP and proprietary innovations. SCT supports clients in meeting operational, regulatory, and sustainability challenges with technologies that advance water reuse, energy efficiency, and emissions reduction.
Website: www.sctwater.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104652683/en/
Contacts
Media Contacts:
Aquadei, LLC
Dr. Mayur M. Dev
info@aqauadei.net
480.694.4709
Sparkle Clean Tech
Priyadarshini Mazumdar
Corporate Communications Manager
priyadarshini@sctwater.com
+91 9987372132
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom